DNA Damage Repair Pathways and Targeted Therapy for Doxorubicin-Resistant Breast Cancer
Frontiers in Bioscience-Landmark · 22.05.2026 · 31 (5)
DOI: 10.31083/fbl47143 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Bioscience-Landmark, online erschienen am 22.05.2026. Verfasst von Yijie Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in Oncology, Suzhou Vocational Health College, 215…. Hauptthemen laut MEDLINE: Doxorubicin, Breast Neoplasms, Drug Resistance, Neoplasm, DNA Repair. Die Arbeit nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Jiangsu Higher Education Institution Innovative Research Team for Science and Technology (2021), Program of Jiangsu Vocational College Engineering Technology Research Center (2023), Program of Suzhou People's Livelihood Technology Projects.
Abstract (Originalsprache)
Breast cancer, characterized by distinctive epidemiological patterns and substantial heterogeneity, continues to be among the leading causes of cancer-related mortality in women. As breast tumors progressively acquire resistance to doxorubicin (DOX), DNA damage repair (DDR) pathways are recognized as key determinants of both DOX efficacy and the onset of resistance. Targeting DDR mechanisms in breast cancer patients with specific repair deficiencies offers the potential for personalized therapeutic approaches. This review first discusses the pivotal roles of five major DNA repair pathways (homologous recombination, nonhomologous end-joining, base excision repair, nucleotide excision repair, and mismatch repair) in the development of DOX resistance. This review aims to establish a theoretical framework and reference for future studies on DDR mechanisms in DOX-resistant breast cancer to advance intervention strategies for resistant breast tumors and to promote further research in this area.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in Oncology, Suzhou Vocational Health College, 215009 Suzhou, Jiangsu, China.
- College of Life Science, North China University of Science and Technology, 063210 Tangshan, Hebei, China.
- Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, 215163 Suzhou, Jiangsu, China.
- Thyroid and Breast Surgery, Wuzhong People's Hospital of Suzhou City, 215128 Suzhou, Jiangsu, China.
Förderung
- The Jiangsu Higher Education Institution Innovative Research Team for Science and Technology (2021)
- Program of Jiangsu Vocational College Engineering Technology Research Center (2023)
- Program of Suzhou People's Livelihood Technology Projects
- Natural Science Key Foundation of the Jiangsu Higher Education Institutions of China
- Research Foundation of Jiangsu Commission of Health
- Dongwu Health Talent Program
- Programs of the Suzhou Vocational Health College
- Project of Jiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in Oncology
Zitieren
APA
Wu, Y., Li, X., Wang, W., Liu, S. B., & Li, X. (2026). DNA Damage Repair Pathways and Targeted Therapy for Doxorubicin-Resistant Breast Cancer. Frontiers in Bioscience-Landmark, 31(5). https://doi.org/10.31083/fbl47143
Vancouver
Wu Y, Li X, Wang W, Liu SB, Li X. DNA Damage Repair Pathways and Targeted Therapy for Doxorubicin-Resistant Breast Cancer. Frontiers in Bioscience-Landmark. 2026;31(5). doi:10.31083/fbl47143
BibTeX
@article{Wu2026,
author = {Wu, Yijie and Li, Xiaoqiang and Wang, Weijie and Liu, Song-Bai and Li, Xiaohua},
title = {DNA Damage Repair Pathways and Targeted Therapy for Doxorubicin-Resistant Breast Cancer},
journal = {Frontiers in Bioscience-Landmark},
year = {2026},
volume = {31},
number = {5},
doi = {10.31083/fbl47143}
}
EUVIMED